INTRODUCTION
NSCLC, tumor
LUNG CANCER, TUMOR, NSCLC
Clinical trials have demonstrated that immune checkpoint inhibitors, when administered as monotherapy or administered together with appropriate chemotherapy regimens, are promising as first‐line treatments for non‐small cell lung cancer (NSCLC) in the absence of driver mutationsIn a Japanese phase II study, nivolumab numerically prolonged OS in the order of tumor programmed death‐ligand 1 (PD‐L1) expression levels of <1%, 1%–49%, and ≥ 50% in previously treated patients with non‐squamous NSCLC.